Notably, despite the excellent clinical performance shown by CD47/SIRPα antibodies, the limitations of antibody drugs, including poor tumor permeability, undesirable oral bioavailability and poor stability, hinder their clinical application [22,23,24,25]. This evidence concerns the gene SIRPA and neoplasm.